Tocilizumab
‘Recovery Trial’ finds anti-arthritis drug reduces severe COVID-19 mortality
The trial found that Baricitinib reduces the mortality of hospitalized patients by 13%. Baricitinib inhibits the enzymes of a specific family of enzyme called the Janus Kinase (JAK) family
COVID-19 treatment: SOLIDARITY trial is restarting with 3 drugs this time
The drug candidates for repurposing are imatinib, a cancer drug; infliximab, an antibody; and artesunate, an anti-malarial drug. The tests seek to explore possible drugs that can be repurposed to treat severely affected COVID-19 patients
- Tiktok ban signed into law
- Mass graves discovered at Nasser Hospital as Israel prepares for Rafah ground invasion
- Columbia University threatens to deploy National Guard to evict Gaza solidarity encampment
- Digital Health in Brazil: imperial threat or promise of sovereignty?
- Tennessee auto workers make history by voting yes to unionize
